The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth

被引:35
|
作者
Montgomery, Elizabeth T. [1 ]
Atujuna, Millicent [2 ]
Krogstad, Emily [1 ]
Hartmann, Miriam [1 ]
Ndwayana, Sheily [2 ]
O'Rourke, Shannon [1 ]
Bekker, Linda-Gail [2 ]
van der Straten, Ariane [1 ,3 ]
Minnis, Alexandra M. [1 ,4 ]
机构
[1] RTI Int, Ctr Global Hlth SSES, Womens Global Hlth Imperat, San Francisco Project Off, San Francisco, CA USA
[2] Desmond Tutu HIV Res Ctr, Cape Town, South Africa
[3] Univ Calif San Francisco, Ctr AIDS Prevent Studies, Dept Med, San Francisco, CA 94143 USA
[4] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA
关键词
South Africa; youth; PrEP; sustained-release long-acting PrEP; implants; injections; DAPIVIRINE VAGINAL RING; PREVENTION; ACCEPTABILITY; TRIAL;
D O I
10.1097/QAI.0000000000001960
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Long-acting injectable and implantable approaches aim to overcome some of the documented challenges with uptake and adherence to current HIV prevention methods. Youth are a key end-user population for these methods. We used qualitative methods to examine product attributes and preferences for current and future long-acting HIV prevention approaches. Methods: Ninety-five South African youth aged 18-24 years, of whom 62 were female and 33 male, completed 50 interviews and 6 focus groups. We purposively selected for previous product experience, including oral pre-exposure prophylaxis, injectable pre-exposure prophylaxis, or the vaginal ring, to ensure participants' opinions were rooted in actual experience. Results: Irrespective of previous method-use experience, gender, or sexual orientation, the majority expressed a preference for prevention methods formulated as injectables or implants. Several mentioned that their top priority in any product was efficacy, and for some, this overrode other concerns; for example, even if they feared pain, an implant or an injectable would be used if fully protective. Although efficacy was a top priority, there was also a clear desire across all subgroups for a product that would not interfere with sex, would stay in the system to provide protection, and that caused minimal burden, or was not apparent to others, and these characteristics were most salient for long-acting methods. Conclusions: Narrative explanations for preferences converged thematically around different dimensions of "invisibility" including invisibility to oneself, one's partner and household members, and community members. End-user preferences can be used to inform product development of long-acting HIV prevention approaches formulated as injections or implants to optimize adherence and impact.
引用
收藏
页码:542 / 550
页数:9
相关论文
共 50 条
  • [1] Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment
    Minnis, Alexandra M.
    Atujuna, Millicent
    Browne, Erica N.
    Ndwayana, Sheily
    Hartmann, Miriam
    Sindelo, Siyaxolisa
    Ngcwayi, Nangamso
    Boeri, Marco
    Mansfield, Carol
    Bekker, Linda-Gail
    Montgomery, Elizabeth T.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 (06)
  • [2] Attribute Preferences for Long-acting Pre-exposure Prophylaxis (PrEP): Results of a Discrete Choice Experiment With South African Youth
    Minnis, Alexandra
    Atujuna, Millicent
    Browne, Erica
    Ndwayana, Sheily
    Hartmann, Miriam
    Sindelo, Siyaxolisa
    Ngcwayi, Nangamso
    Boeri, Marco
    Mansfield, Carol
    Bekker, Linda-Gail
    Montgomery, Elizabeth
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 27 - 27
  • [3] Conjoint Analysis of User Acceptability of Sustained Long-Acting Pre-Exposure Prophylaxis for HIV
    Schieffer, Robert J.
    Bryndza Tfaily, Ewa
    D'Aquila, Richard
    Greene, George J.
    Carballo-Dieguez, Alex
    Giguere, Rebecca
    Tagliaferri Rael, Christine
    Kiser, Patrick F.
    Hope, Thomas J.
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2022, 38 (04) : 336 - 345
  • [4] Interrogating the promise of long-acting HIV pre-exposure prophylaxis
    Pike, Carey
    Bekker, Linda-Gail
    [J]. TRENDS IN MOLECULAR MEDICINE, 2023, 29 (02) : 93 - 98
  • [5] Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis
    Prather, Caitlin
    Jeon, Chaeok
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (21) : 1898 - 1905
  • [6] Design of an Implant for Long-Acting HIV Pre-Exposure Prophylaxis: Input from South African Health Care Providers
    Krogstad, Emily A.
    Montgomery, Elizabeth T.
    Atujuna, Millicent
    Minnis, Alexandra M.
    O'Rourke, Shannon
    Ahmed, Khatija
    Bekker, Linda-Gail
    van der Straten, Ariane
    [J]. AIDS PATIENT CARE AND STDS, 2019, 33 (04) : 157 - 166
  • [7] Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV
    Zondo, Nomusa M.
    Sobia, Parveen
    Sivro, Aida
    Ngcapu, Sinaye
    Ramsuran, Veron
    Archary, Derseree
    [J]. FRONTIERS IN GENETICS, 2022, 13
  • [8] Cabotegravir-Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
    Pepperrell, Toby
    Cross, Samuel
    Hill, Andrew
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (01):
  • [9] Tenofovir alafenamide fumarate loaded long-acting microsphere for HIV pre-exposure prophylaxis
    Pawar, Manoj A.
    Abadi, Leila Fotooh
    Rojekar, Satish, V
    Yawalkar, Ankita N.
    Kulkarni, Smita S.
    Vavia, Pradeep R.
    [J]. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2023, 87
  • [10] Statistical approaches to accelerate the development of long-acting antiretrovirals for HIV pre-exposure prophylaxis
    Glidden, David V.
    [J]. CURRENT OPINION IN HIV AND AIDS, 2020, 15 (01) : 56 - 60